Sachdev Thomas

1.9k total citations
58 papers, 1.3k citations indexed

About

Sachdev Thomas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sachdev Thomas has authored 58 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Sachdev Thomas's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Treatment and Pharmacology (10 papers). Sachdev Thomas is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Treatment and Pharmacology (10 papers). Sachdev Thomas collaborates with scholars based in United States, Canada and China. Sachdev Thomas's co-authors include Everett E. Vokes, David R. Gandara, Barbara J. Gitlitz, Marianna Koczywas, Donald G. Albert, Afshin Dowlati, L. Seigel, Rogério Lilenbaum, Suresh S. Ramalingam and Karsten Witt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Sachdev Thomas

57 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sachdev Thomas United States	18	874	510	483	132	120	58	1.3k
Sophia Abraham United States	8	569 0.7×	491 1.0×	832 1.7×	201 1.5×	80 0.7×	12	1.6k
Tindara Franchina Italy	19	749 0.9×	633 1.2×	487 1.0×	311 2.4×	52 0.4×	60	1.3k
Vincenzo Sforza Italy	18	680 0.8×	362 0.7×	380 0.8×	194 1.5×	110 0.9×	58	1.2k
Agnese Montanino Italy	18	802 0.9×	495 1.0×	286 0.6×	422 3.2×	151 1.3×	42	1.2k
Michael E. Menefee United States	15	610 0.7×	209 0.4×	484 1.0×	181 1.4×	59 0.5×	45	1.3k
Annette Frost Germany	14	747 0.9×	493 1.0×	462 1.0×	184 1.4×	46 0.4×	29	1.4k
Francisco Javier Ramos Spain	15	625 0.7×	422 0.8×	771 1.6×	192 1.5×	72 0.6×	42	1.4k
Luca Moscetti Italy	20	1.1k 1.3×	873 1.7×	355 0.7×	361 2.7×	97 0.8×	98	1.6k
A. Y. Chang United States	17	724 0.8×	494 1.0×	230 0.5×	76 0.6×	106 0.9×	40	1.3k
Jiuda Zhao China	17	764 0.9×	573 1.1×	337 0.7×	274 2.1×	92 0.8×	88	1.3k

Countries citing papers authored by Sachdev Thomas

Since Specialization

Citations

This map shows the geographic impact of Sachdev Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sachdev Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sachdev Thomas more than expected).

Fields of papers citing papers by Sachdev Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sachdev Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sachdev Thomas. The network helps show where Sachdev Thomas may publish in the future.

Co-authorship network of co-authors of Sachdev Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Sachdev Thomas. A scholar is included among the top collaborators of Sachdev Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sachdev Thomas. Sachdev Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hosein, Peter J., Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2025). Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 43(4_suppl). 715–715. 1 indexed citations

Thomas, Sachdev, Laurel A. Habel, Jennifer M. Suga, et al.. (2024). Evaluation of a predictive biomarker for antibody drug conjugates (ADCs).. Journal of Clinical Oncology. 42(16_suppl). 3140–3140. 1 indexed citations

Pan, Minggui, Zheyang Zhang, Nam Q. Bui, et al.. (2024). PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma. PubMed. 2(1). 9–9. 3 indexed citations

Pan, Minggui, Chen Jiang, Zheyang Zhang, et al.. (2023). Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies. Cancers. 15(10). 2665–2665. 9 indexed citations

Pan, Minggui, Zheyang Zhang, Nam Q. Bui, et al.. (2023). Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma. Clinical Cancer Research. 30(2). 413–419. 5 indexed citations

Thomas, Sachdev, Amit Arora, Elaine Chung, et al.. (2023). Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.. Journal of Clinical Oncology. 41(6_suppl). 261–261. 1 indexed citations

Kasthuri, Raj S., Shruti Chaturvedi, Sachdev Thomas, et al.. (2022). Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument. Blood Advances. 6(14). 4301–4309. 1 indexed citations

Jatoi, Aminah, Rui Qin, Daniel Satele, et al.. (2016). “Enjoy glass of wine before eating:” a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Supportive Care in Cancer. 24(9). 3739–3746. 8 indexed citations

Sweis, Randy F., Sachdev Thomas, Bruce Bank, et al.. (2016). Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 8(2). e513–e513. 22 indexed citations

10.

Zhao, Yujie, Nathan R. Foster, Jeffrey P. Meyers, et al.. (2014). A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of Thoracic Oncology. 10(1). 172–180. 38 indexed citations

11.

Jasielec, Jagoda, Amy Kimball, Kenneth S. Cohen, et al.. (2014). Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV).. Journal of Clinical Oncology. 32(15_suppl). 8567–8567. 2 indexed citations

12.

Dy, Grace K., Julian R. Molina, Yingwei Qi, et al.. (2014). NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status. Journal of Thoracic Oncology. 9(8). 1146–1153. 6 indexed citations

13.

Campbell, Nicholas, Rangesh Kunnavakkam, Natasha B. Leighl, et al.. (2012). Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 78(1). 76–80. 45 indexed citations

14.

Dranitsaris, George, et al.. (2012). Evaluating the Impact of Bevacizumab Maintenance Therapy on Overall Survival in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(2). 120–127. 5 indexed citations

15.

Thomas, Sachdev, Suprith Badarinath, Richard H. Greenberg, et al.. (2012). MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). TPS3635–TPS3635. 5 indexed citations

16.

Traynor, Anne M., Ju-Whei Lee, Sachdev Thomas, et al.. (2009). A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Investigational New Drugs. 28(1). 91–97. 101 indexed citations

17.

Clark, Joseph I., Craig C. Hofmeister, John D. Norton, et al.. (2009). Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. American Journal of Clinical Oncology. 32(4). 396–400. 3 indexed citations

18.

Lilenbaum, Rogério, Rita Axelrod, Sachdev Thomas, et al.. (2008). Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2. Journal of Clinical Oncology. 26(6). 863–869. 149 indexed citations

19.

Jatoi, Aminah, Shaker R. Dakhil, Nathan R. Foster, et al.. (2008). Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). Journal of Thoracic Oncology. 3(5). 516–520. 26 indexed citations

20.

Lee, Richard T., Maha Hussain, Nancy B. Davis, et al.. (2008). A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer. Clinical Genitourinary Cancer. 6(1). 21–24. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact